MeiraGTx Holdings (MGTX) Gross Margin (2024 - 2025)
MeiraGTx Holdings posted quarterly Gross Margin of 99.37% for Q4 2025, up 5456.0% year-on-year from 1.79% in Q4 2024, and up 320.01% on a QoQ basis from 23.66% in Q3 2025.
MeiraGTx Holdings (MGTX) has 2 years of Gross Margin data on file, last reported at 99.37% in Q4 2025.
- For the quarter ending Q4 2025, Gross Margin rose 5456.0% year-over-year to 99.37%; the trailing twelve-month figure through Dec 2025 stood at 84.86% (changed N/A YoY), and the FY2025 full-year result was 94.05%, up 6554.0% from the prior year.
- Gross Margin for Q4 2025 stood at 99.37%, up from 23.66% in the prior quarter.
- Across five years, Gross Margin topped out at 99.37% in Q4 2025 and bottomed at 9.85% in Q3 2024.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Gross Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | 79.04% |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 86.85% |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 91.79% |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 82.22% |
| 10 | MeiraGTx Holdings | 856.58 Mn | 790.65 Mn | 74.89 Mn | 99.37% |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 99.37% |
| Sep 30, 2025 | 23.66% |
| Jun 30, 2025 | 27.50% |
| Dec 31, 2024 | 44.81% |
| Sep 30, 2024 | -9.85% |